

# PRESS RELEASE

innate pharma

## INNATE PHARMA TO PRESENT UPDATED INTERIM PHASE 2 EFFICACY RESULTS OF LACUTAMAB IN MYCOSIS FUNGOIDES AT THE INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA

- ***Efficacy results of lacutamab in Mycosis Fungoides according to updated lymph node classification in the TELLOMAK Phase 2 study in advanced cutaneous T cell lymphomas***

**Marseille, France, June 12, 7:00 AM CEST**

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“**Innate**” or the “**Company**”) today announced that interim efficacy results from the TELLOMAK Phase 2 study of lacutamab in advanced Mycosis Fungoides will be presented at the 17<sup>th</sup> International Conference on Malignant Lymphoma, being held in Lugano, June 13 – 17, 2023. Efficacy results will be presented according to updated lymph node classification.

### **Presentation details**

**Title:** [Lacutamab in patients with advanced mycosis fungoides \(MF\): efficacy results according to updated lymph node \(LN\) classification in the TELLOMAK study](#)

**Session:** Focus on...T-Cell Lymphomas

**Date and time:** 15/06/2023, 17:50

**Location:** Room A

**Speaker:** Dr. Pierluigi Porcu, Director, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Sidney Kimmel Cancer Center, Jefferson Health Philadelphia, US


In addition, a Trial in Progress abstract of KILT, the Phase 2 study of lacutamab in peripheral T-cell lymphoma led by The Lymphoma Study Association (LYSA) has been published in the [17-ICML abstract book available online](#).

### **About Lacutamab**

Lacutamab is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL). Rare cutaneous lymphomas of T lymphocytes have a poor prognosis with few efficacious and safe therapeutic options at advanced stages.

KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up to 90% of patients with certain aggressive CTCL subtypes, in particular, Sézary syndrome. It is expressed by up to 50% of patients with mycosis fungoides and peripheral T-cell lymphoma (PTCL). It has a restricted expression on normal tissues.

Lacutamab is granted European Medicines Agency (EMA) PRIME designation and US Food and Drug Administration (FDA) granted Fast Track designation for the treatment of patients with relapsed or refractory Sézary syndrome who have received at least two prior systemic therapies.



# PRESS RELEASE

innate pharma

Lacutamab is granted orphan drug status in the European Union and in the United States for the treatment of CTCL.

## About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET<sup>®</sup> (**A**ntibody-based **NK** cell **E**ngager **T**herapeutics) proprietary platform.

Innate's portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET<sup>®</sup> multi-specific NK cell engagers to address multiple tumor types.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.


Learn more about Innate Pharma at [www.innate-pharma.com](http://www.innate-pharma.com) and follow us on [Twitter](#) and [LinkedIn](#).

## Information about Innate Pharma shares

<b>ISIN code</b>	FR0010331421
<b>Ticker code</b>	Euronext: IPH Nasdaq: IPHA
<b>LEI</b>	9695002Y8420ZB8HJE29

## Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website <http://www.amf-france.org> or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Annual



# PRESS RELEASE

**innate pharma**

---

Report on Form 20-F for the year ended December 31, 2022, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

## **For additional information, please contact:**

### **Investors**

#### **Innate Pharma**

Henry Wheeler

Tel.: +33 (0)4 84 90 32 88

[Henry.wheeler@innate-pharma.fr](mailto:Henry.wheeler@innate-pharma.fr)

### **Media Relations**

#### **NewCap**

Arthur Rouillé

Tel.: +33 (0)1 44 71 00 15

[innate@newcap.eu](mailto:innate@newcap.eu)